114 related articles for article (PubMed ID: 32394766)
1. Cytoplasmic levels of high mobility group A2 determine survival prognoses in breast cancer patients.
Heilmann T; Vondung F; Borzikowsky C; Krüger S; Elessawy M; Alkatout I; Wenners A; Bauer M; Klapper W; Röcken C; Maass N; Schem C; Trauzold A
Int J Biol Markers; 2020 Jun; 35(2):20-28. PubMed ID: 32394766
[TBL] [Abstract][Full Text] [Related]
2. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
Wu J; Zhang S; Shan J; Hu Z; Liu X; Chen L; Ren X; Yao L; Sheng H; Li L; Ann D; Yen Y; Wang J; Wang X
Cancer Lett; 2016 Jul; 376(2):284-92. PubMed ID: 27063096
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression.
Gundlach JP; Hauser C; Schlegel FM; Willms A; Halske C; Röder C; Krüger S; Röcken C; Becker T; Kalthoff H; Trauzold A
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3313-3324. PubMed ID: 34302528
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma.
Wei R; Shang Z; Leng J; Cui L
J Cancer Res Ther; 2016; 12(4):1291-1297. PubMed ID: 28169242
[TBL] [Abstract][Full Text] [Related]
5. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression.
Binabaj MM; Soleimani A; Rahmani F; Avan A; Khazaei M; Fiuji H; Soleimanpour S; Ryzhikov M; Ferns GA; Bahrami A; Hassanian SM
Gene; 2019 Jul; 706():131-139. PubMed ID: 31055021
[TBL] [Abstract][Full Text] [Related]
7. High mobility group A protein-2 as a tumor cancer diagnostic and prognostic marker: a systematic review and meta-analysis.
Thi-Hai Pham Y; Utuama O; Thomas CE; Park JA; La Vecchia C; Risch HA; Tran CT; Le TV; Boffetta P; Raskin L; Luu HN
Eur J Cancer Prev; 2020 Nov; 29(6):565-581. PubMed ID: 32898013
[TBL] [Abstract][Full Text] [Related]
8. High-mobility-group A2 overexpression provokes a poor prognosis of gastric cancer through the epithelial-mesenchymal transition.
Lee J; Ha S; Jung CK; Lee HH
Int J Oncol; 2015; 46(6):2431-8. PubMed ID: 25845850
[TBL] [Abstract][Full Text] [Related]
9. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2.
Sun M; Gomes S; Chen P; Frankenberger CA; Sankarasharma D; Chung CH; Chada KK; Rosner MR
Oncogene; 2014 Jul; 33(27):3528-37. PubMed ID: 23975428
[TBL] [Abstract][Full Text] [Related]
10. HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathway.
Xu J; Fang X; Long L; Wang S; Qian S; Lyu J
Cancer Biol Ther; 2021 Jan; 22(1):5-11. PubMed ID: 33307962
[TBL] [Abstract][Full Text] [Related]
11. High mobility group protein A2 overexpression indicates poor prognosis for cancer patients: a meta-analysis.
Nie D; Zhang L; Guo Q; Mao X
Oncotarget; 2018 Jan; 9(1):1237-1247. PubMed ID: 29416690
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of HMGA2 in renal carcinoma].
Liu Y; Fu QZ; Pu L; Song LL; Lyu GY; Liu J; Wang Z; Wang Z
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):127-132. PubMed ID: 28219208
[No Abstract] [Full Text] [Related]
13. Metformin alleviates breast cancer through targeting high-mobility group AT-hook 2.
Li Y; Wang D; Ren H; Feng W
Thorac Cancer; 2020 Mar; 11(3):686-692. PubMed ID: 32031335
[TBL] [Abstract][Full Text] [Related]
14. High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma.
Fang CY; Liew PL; Chen CL; Lin YH; Fang CL; Chen WY
Anticancer Res; 2017 Apr; 37(4):1891-1899. PubMed ID: 28373457
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer.
Kong D; Su G; Zha L; Zhang H; Xiang J; Xu W; Tang Y; Wang Z
Med Oncol; 2014 Aug; 31(8):130. PubMed ID: 25037576
[TBL] [Abstract][Full Text] [Related]
16. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
17. Elevated high mobility group A2 expression in liver cancer predicts poor patient survival.
Zhao YC; Jiao Y; Li YQ; Fu Z; Yang ZY; He M
Rev Esp Enferm Dig; 2020 Jan; 112(1):27-33. PubMed ID: 31823639
[TBL] [Abstract][Full Text] [Related]
18. High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer.
Hawsawi O; Henderson V; Burton LJ; Dougan J; Nagappan P; Odero-Marah V
Biochem Biophys Res Commun; 2018 Sep; 504(1):196-202. PubMed ID: 30177390
[TBL] [Abstract][Full Text] [Related]
19. microRNA-98 inhibits the proliferation, invasion, migration and promotes apoptosis of breast cancer cells by binding to HMGA2.
Wang MJ; Zhang H; Li J; Zhao HD
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30049846
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and significance of HMGA2 expression in oesophageal adenocarcinoma.
Mito JK; Agoston AT; Dal Cin P; Srivastava A
Histopathology; 2017 Dec; 71(6):909-917. PubMed ID: 28710822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
